Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

10.80USD
21 Jun 2018
Change (% chg)

$-0.20 (-1.82%)
Prev Close
$11.00
Open
$11.00
Day's High
$11.15
Day's Low
$10.68
Volume
79,808
Avg. Vol
97,339
52-wk High
$29.00
52-wk Low
$9.85

Select another date:

Wed, May 9 2018

BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91

* PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Paratek Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* PARATEK ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

BRIEF-Highbridge Capital Management Reports 6.54 Pct Passive Stake In Paratek Pharmaceuticals

* HIGHBRIDGE CAPITAL MANAGEMENT, LLC REPORTS 6.54 PERCENT PASSIVE STAKE IN PARATEK PHARMACEUTICALS INC AS OF APRIL 23, 2018 - SEC FILING Source : https://bit.ly/2HIcM0E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors

* PARATEK APPOINTS ROLF K. HOFFMAN TO COMPANY’S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA

* PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA

BRIEF-Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78

* PARATEK PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REMAINS ON TRACK FOR COMMERCIAL LAUNCH BY FIRST QUARTER 2019

BRIEF-Paratek Completes Submission Of New Drug Applications To U.S.FDA

* PARATEK COMPLETES SUBMISSION OF NEW DRUG APPLICATIONS TO U.S. FOOD AND DRUG ADMINISTRATION FOR ORAL AND INTRAVENOUS OMADACYCLINE FOR PNEUMONIA AND SKIN INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Paratek Announces $50.0 Mln Public Offering Of Common Stock

* PARATEK PHARMACEUTICALS INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS SHARES OF COMMON STOCK Source text for Eikon: Further company coverage:

Select another date: